Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 80
Filter
1.
J Immunol Methods ; 378(1-2): 81-7, 2012 Apr 30.
Article in English | MEDLINE | ID: mdl-22366633

ABSTRACT

Monitoring T cells in combination with humoral response may be of value to predict clinical protection and cross-protective immunity after influenza vaccination. Elispot technique which measures cytokine produced after antigen-specific T cell stimulation is used routinely to detect and characterize anti-viral T cells. We found that the preservative thimerosal present in most H1N1 pandemic vaccines, induced in vitro abortive activation of T cells followed by cell death leading to false-positive results with the Elispot technique. The size of the spots, usually not measured in routine analysis, appears to be a discriminative criterion to detect this bias. Multi-dose vials of vaccine containing thimerosal remain important for vaccine delivery and our results alert about false-positive results of Elispot to monitor the clinical efficacy of these vaccines. We showed that this finding extends for other T cell monitoring techniques based on cytokine production such as ELISA. Although measuring in vitro immune response using the whole vaccine used for human immunization directly reflects in vivo global host response to the vaccine, the present study strongly supports the use of individual vaccine components for immune monitoring due to the presence of contaminants, such as thimerosal, leading to a bias in interpretation of the results.


Subject(s)
Antigens, Viral/immunology , Enzyme-Linked Immunospot Assay/methods , Influenza A Virus, H1N1 Subtype/immunology , Influenza Vaccines/immunology , Influenza, Human/immunology , T-Lymphocytes/immunology , Thimerosal/administration & dosage , Cell Death/immunology , Cross Protection/immunology , False Positive Reactions , Humans , Influenza Vaccines/administration & dosage , Influenza, Human/prevention & control , Interferon-gamma/immunology , Leukocytes, Mononuclear/immunology , Lymphocyte Activation/immunology , Pandemics , Thimerosal/immunology , Vaccination/methods
2.
Cancer Metastasis Rev ; 30(1): 83-95, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21249423

ABSTRACT

The immune system regulates angiogenesis in cancer with both pro- and antiangiogenic activities. The induction of angiogenesis is mediated by tumor-associated macrophages and myeloid-derived suppressor cells (MDSC) which produce proinflammatory cytokines, endothelial growth factors (VEGF, bFGF…), and protease (MMP9) implicated in neoangiogenesis. Some cytokines (IL-6, IL-17…) activated Stat3 which also led to the production of VEGF and bFGF. In contrast, other cytokines (IFN, IL-12, IL-21, and IL-27) display an antiangiogenic activity. Recently, it has been shown that some antiangiogenic molecules alleviates immunosuppression associated with cancer by decreasing immunosuppressive cells (MDSC, regulatory T cells), immunosuppressive cytokines (IL-10, TGFß), and inhibitory molecules on T cells (PD-1). Some of these broad effects may result from the ability of some antiangiogenic molecules, especially cytokines to inhibit the Stat3 transcription factor. The association often observed between angiogenesis and immunosuppression may be related to hypoxia which induces both neoangiogenesis via activation of HIF-1 and VEGF and favors the intratumor recruitment and differentiation of regulatory T cells and MDSC. Preliminary studies suggest that modulation of immune markers (intratumoral MDSC and IL-8, peripheral regulatory T cells…) may predict clinical response to antiangiogenic therapy. In preclinical models, a synergy has been observed between antiangiogenic molecules and immunotherapy which may be explained by an improvement of immune status in tumor-bearing mice after antiangiogenic therapy. In preclinical models, antiangiogenic molecules promoted intratumor trafficking of effector cells, enhance endogenous anti-tumor response, and synergyzed with immunotherapy protocols to cure established murine tumors. All these results warrant the development of clinical trials combining antiangiogenic drugs and immunotherapy.


Subject(s)
Angiogenesis Inhibitors/pharmacology , Immunity/drug effects , Neoplasms/blood supply , Neoplasms/therapy , Neovascularization, Pathologic/therapy , Angiogenesis Inhibitors/therapeutic use , Animals , Biomarkers, Pharmacological , Combined Modality Therapy , Drug Synergism , Humans , Hypoxia/immunology , Immunotherapy , Neoplasms/immunology , Neovascularization, Pathologic/drug therapy , Neovascularization, Pathologic/immunology
3.
Clin Exp Immunol ; 150(1): 114-23, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17680822

ABSTRACT

In a series of 84 head and neck patients, a statistically significant correlation was observed between high serum soluble interleukin (IL)-2 receptor alpha (sIL-2Ralpha) (P = 0.034) and metalloproteinase-9 (MMP-9) concentrations (P = 0.036) at diagnosis and a shorter survival of these patients. As MMP-9 has been shown to mediate cleavage of IL-2Ralpha (CD25) by preactivated T cells, we looked for a relationship between MMP-9 expression and soluble IL-2Ralpha serum concentrations in these cancer patients. We did not find any correlation between intratumoral expression of MMP-9 or serum MMP-9 concentrations and serum sIL-2Ralpha levels. These results led us to reassess the role of MMP-9 in the release of sIL-2Ralpha. Treatment of Kit225 leukaemic cells with recombinant MMP-9 slightly decreased membrane CD25 expression and was associated with an increased concentration of sIL-2Ralpha in the supernatants. However, using a selective inhibitor of MMP-9 we did not succeed in specifically inhibiting the release of sIL-2Ralpha by the Kit225 cell line or by phytohaemagglutinin (PHA)-activated peripheral blood mononuclear cells. In addition, in a preclinical mouse model, basal serum sIL-2Ralpha concentrations and sIL-2Ralpha production by activated cells were not altered in MMP-9-deficient mice compared to wild-type mice. Interestingly, a broad spectrum metalloproteinase inhibitor inhibited the release of sIL-2Ralpha by PHA-activated peripheral blood mononuclear cells, suggesting that in contrast with current views concerning the major role of MMP-9 in the cleavage of membrane IL-2Ralpha, other proteases are involved in the shedding of sIL-2Ralpha. MMP-9 and sIL-2Ralpha appear therefore as independent prognostic markers in head and neck cancers.


Subject(s)
Biomarkers, Tumor/blood , Carcinoma, Squamous Cell/blood , Head and Neck Neoplasms/blood , Interleukin-2 Receptor alpha Subunit/blood , Matrix Metalloproteinase 9/blood , Animals , Carcinoma, Squamous Cell/immunology , Cells, Cultured , Head and Neck Neoplasms/immunology , Humans , Lymphocyte Activation/immunology , Matrix Metalloproteinase 9/pharmacology , Matrix Metalloproteinase Inhibitors , Mice , Mice, Inbred C57BL , Neoplasm Staging , Prognosis , Prospective Studies , Protease Inhibitors/pharmacology , Recombinant Proteins/pharmacology , Solubility , Survival Analysis , T-Lymphocytes/immunology , Tumor Cells, Cultured
4.
J Chem Phys ; 122(18): 181104, 2005 May 08.
Article in English | MEDLINE | ID: mdl-15918685

ABSTRACT

A new algorithm for solving integral equations of the theory of liquids at fixed pressure is introduced. Combining this technique with the Lee's star function approximation for the chemical potentials, we obtain an efficient method to investigate fluid-phase diagrams of binary mixtures. We have tested the capabilities of such technique to study symmetric and asymmetric phase diagrams in nonadditive hard spheres and Lennard-Jones mixtures. We find that the integral equation theories, although approximate, can provide a flexible tool to determine the fluid-phase diagrams whose accuracy is critically dependent on the quality of the closure and of the resulting chemical potentials.

5.
Pediatr Med Chir ; 24(5): 390-1, 2002.
Article in English | MEDLINE | ID: mdl-12494543

ABSTRACT

Sickle cell disease is a rare condition in italian patients and even rarer are its complications, in particular Salmonella osteomyelitis. We describe a case of a Ghanaian child with sickle cell disease who developed osteomyelitis due to Salmonella panama, treated successfully with surgical debridement, followed by a prolonged period of specific antibiotic therapy.


Subject(s)
Anemia, Sickle Cell/complications , Femur/microbiology , Femur/surgery , Osteomyelitis/complications , Osteomyelitis/microbiology , Salmonella Infections/complications , Anti-Bacterial Agents , Combined Modality Therapy , Drug Therapy, Combination/therapeutic use , Female , Humans , Infant , Osteomyelitis/therapy , Salmonella Infections/drug therapy , Surgical Procedures, Operative
7.
J Nephrol ; 14(1): 36-42, 2001.
Article in English | MEDLINE | ID: mdl-11281343

ABSTRACT

Hyperhomocysteinemia (Hcy) is an independent factor of cardiovascular disease, which is the main cause of morbidity and mortality both in uremic and kidney transplant patients. The aim of the study was to determine Hcy, plasminogen activator inhibitor (PAI-1) and lipoprotein (a) (Lp(a)) serum levels in 70 patients with a well functioning renal transplant. We also verified whether these levels were modified by a multivitamin therapy. The genetic polymorphism of the methylenetetrahydrofolate reductase (MTHFR) enzyme which plays a main role in Hcy metabolism, was studied as well. We found Hcy, PAI-1 and Lp(a) levels significantly elevated with respect to healthy control subjects. The thermolabile form of the MTHFR enzyme was linked to higher Hcy levels. After a short time on therapy with B6, B12 and folic acid vitamins, Hcy and PAI-1 decreased to normal levels. The authors conclude that high Hcy levels could be a relevant covariate for cardiovascular disease in transplant patients and they suggest that vitamin supplementation be recommended as a part of therapy.


Subject(s)
Cardiovascular Diseases/epidemiology , Hyperhomocysteinemia/epidemiology , Kidney Transplantation , Case-Control Studies , Female , Folic Acid/therapeutic use , Humans , Hyperhomocysteinemia/prevention & control , Lipoprotein(a)/blood , Male , Methylenetetrahydrofolate Reductase (NADPH2) , Middle Aged , Oxidoreductases Acting on CH-NH Group Donors/genetics , Plasminogen Activator Inhibitor 1/blood , Polymorphism, Genetic , Pyridoxine/therapeutic use , Risk Factors , Vitamin B 12/therapeutic use
8.
Vet Res ; 31(5): 507-15, 2000.
Article in English | MEDLINE | ID: mdl-11050746

ABSTRACT

Early detection of osteoarthritis in horses represents a challenge for equine practitioners. Several biological markers have been implicated in the pathological processes involved in articular cartilage destruction. To further document cartilage matrix proteases production, synovial fluid was collected from 14 horses (90 joints) before they were subjected to euthanasia. Growth macroscopic examination of the joints gave information on cartilage alterations. Samples were analyzed for matrix metalloproteinase (MMPs) activities by gelatin zymography and tumor necrosis factor alpha (TNF-alpha) cytotoxicity using L929 cells. Significant increase of MMP-9 monomer and dimer were found in synovial fluids of joints with severe cartilage alterations. On the contrary, the activity of TNF-alpha was not correlated to the degree of joint damage. The levels of MMP-9 monomer and dimer in the synovial fluid could reflect cartilage alteration in arthritis in the horse.


Subject(s)
Cartilage, Articular/pathology , Horse Diseases/diagnosis , Metalloendopeptidases/analysis , Osteoarthritis/veterinary , Synovial Fluid/chemistry , Tumor Necrosis Factor-alpha/analysis , Animals , Biomarkers/analysis , Cell Line , Electrophoresis, Polyacrylamide Gel/veterinary , Horses , Mice , Osteoarthritis/diagnosis , Synovial Fluid/cytology , Synovial Fluid/enzymology
9.
Br J Cancer ; 81(8): 1344-50, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10604731

ABSTRACT

New strategies for cancer therapy must be developed, especially in severe neoplasms such as malignant pleural mesothelioma. Animal models of cancer, as close as possible to the human situation, are needed to investigate novel therapeutical approaches. Orthotopic transplantation of cancer cells is then relevant and efforts should be made to follow up tumour evolution in animals. In the present study, we developed a method for the orthotopic growth of mesothelioma cells in the pleural cavity of Fischer 344 and nude rats, along with a procedure for clinical survey. Two mesothelioma cell lines, of rat and human origin, were inoculated by transthoracic puncture. Body weight determination and chest X-ray analyses permitted the follow-up of tumour evolution by identifying different stages. Autopsies showed that tumours localized on the whole pleural cavity (diaphragm, parietal pleura), mediastinum and pericardium. Tumour morphology and antigenic characteristics were consistent with those of the inoculated cells and were similar in both types of rats inoculated with the same cell type. These results demonstrate that mesothelioma formation in rats can be followed up by clinical and radiographic survey after gentle intrathoracic inoculation of mesothelioma cells, thus allowing the definition of stages of interest for further experimental trials.


Subject(s)
Lung Neoplasms/diagnostic imaging , Mesothelioma/pathology , Pleural Neoplasms/diagnostic imaging , Animals , Humans , Lung Neoplasms/pathology , Neoplasm Transplantation , Pleural Neoplasms/pathology , Radiography, Thoracic , Rats , Rats, Inbred F344 , Rats, Nude , Tumor Cells, Cultured
11.
Biochem Pharmacol ; 54(3): 357-63, 1997 Aug 01.
Article in English | MEDLINE | ID: mdl-9278094

ABSTRACT

Ribavirin (RIBV) is a useful drug in the treatment of chronic type C hepatitis but displays a toxicity for red blood cells (RBC), which limits its dosage and necessitates withdrawal in some patients. Selective concentration of RIBV in liver should improve therapeutic results. Liver targeting can be achieved by coupling the drug to galactosyl-terminating peptides, which specifically enter hepatocytes. In the present work, we conjugated RIBV to lactosaminated poly-L-lysine (L-Poly(Lys)), a hepatotropic carrier enabling intramuscular (IM) administration of conjugates. The L-Poly(Lys)-RIBV conjugate had a heavy drug load (312-327 microg of RIBV in 1 mg of conjugate) and was very soluble in 0.9% NaCl (200 mg/mL). The conjugate was devoid of acute toxicity in mouse. When incubated with human or mouse blood, it did not release the drug. After IM administration to mice, the conjugate was selectively taken up by the liver, where the drug was released in a pharmacologically active form. This was demonstrated using mice infected with a strain of murine hepatitis virus (MHV) sensitive to RIBV. Coupled RIBV, IM injected, inhibited MHV replication in liver at a daily dose two to three times lower than that of the free drug. In mice IM injected with a conjugate tritiated in the RIBV moiety, the ratios between the levels of radioactivity in liver and RBC were two times higher than in animals injected with free tritiated RIBV. In conclusion, the present results support the possibility that the chemotherapeutic index of RIBV in chronic type C hepatitis can be increased by conjugation with L-Poly(Lys).


Subject(s)
Amino Sugars/administration & dosage , Antiviral Agents/administration & dosage , Hepatitis/drug therapy , Liver/drug effects , Polylysine/administration & dosage , Ribavirin/administration & dosage , Animals , Antiviral Agents/toxicity , Cells, Cultured , Drug Stability , Erythrocytes/drug effects , Female , Hepatitis/metabolism , Hepatitis/virology , Hepatitis C/drug therapy , Humans , Injections, Intramuscular , Liver/metabolism , Liver/virology , Mice , Mice, Inbred BALB C , Ribavirin/chemistry , Ribavirin/toxicity , Tritium
12.
Eur J Clin Chem Clin Biochem ; 35(8): 633-5, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9298355

ABSTRACT

The polymerase chain reaction (PCR) has been successfully employed for the laboratory analyses of genetic and infectious disorders using DNA extracted from paraffin-embedded tissues. However, fixative type and fixation time influenced PCR reactions and in some circumstances amplification fragments could not be efficiently generated. In this study, we determined the effects of three commonly used fixatives including ethanol, formalin and Histochoice, on the PCR amplification of DNA from paraffin-embedded breast cancer tissue. The effect of fixatives and fixation times was measured by the ability of the extracted DNA to serve as a template for the amplification of 280 and 530 base pair DNA fragments. On amplifying DNA, positive reactions were uniformly seen in the ethanol specimens. The next best fixative was Histochoice with positive results almost constantly observed in the PCR reactions performed. Formalin fixation sometimes compromised DNA amplification. Our results are consistent with previous reports investigating the effect of ethanol and formalin fixation on DNA amplification by PCR. Moreover, this is the first study showing that paraffin-embedded tissues fixed with Histochoice can be efficiently used for PCR gene amplification.


Subject(s)
Breast Neoplasms/chemistry , Ethanol , Fixatives , Formaldehyde , Paraffin Embedding , Polymerase Chain Reaction , Breast Neoplasms/diagnosis , Breast Neoplasms/genetics , Female , Histocytochemistry/methods , Humans , Polymerase Chain Reaction/methods , Tissue Fixation/methods
13.
Pediatr Med Chir ; 19(3): 159-63, 1997.
Article in Italian | MEDLINE | ID: mdl-9340605

ABSTRACT

UNLABELLED: There are very few reports about the feasibility of maternal milk feeding in very low birthweight preterm infants (VLBW), especially in twins. Therefore we conducted a cohort retrospective study to evaluate the feeding patterns of the 226 VLBW discharged from our neonatal intensive care unit from 1987 to 1996. Their gestational age was 30 +/- 2.6 weeks, birthweight 1166 +/- 224 g and they were hospitalized for 67 +/- 37 days (means +/- 1 SD). Of the 226 VLBW 49% were males, 39% had birthweight below 10 degrees centile for gestational age and 56% were born to non-residents in our area. There were 181 single births and 45 (20%) multiple births, of which 16 from pregnancies with 3 or more fetuses. Of the total cases 22% were discharged feeding maternal milk (MM) exclusively and 21% on mixed-feeding, maternal + formula milk (FM). Percentages were respectively 23% and 18% for single newborns, 11% and 29% for twins. Singletons and twins were discharged on FM with comparable percentages (59 and 60%). With passing years we have noticed a significant increase (chi square for linear trend < 0.01) for maternal milk feeding. In the last 2 years 49% of singletons and 38% of twins were discharged on MM, 14% and 24% on MM + FM, and only 37% and 38% on FM only. Between singletons and twins there were no statistically significant differences as far as feeding at discharge is concerned. CONCLUSIONS: most mothers, if correctly informed and encouraged, are able to breast-feed, exclusively or partially, their VLBW offspring, including twins, in the first months of life.


Subject(s)
Breast Feeding , Infant, Very Low Birth Weight , Breast Feeding/statistics & numerical data , Cohort Studies , Feasibility Studies , Female , Humans , Infant Food , Infant, Newborn , Infant, Premature , Male , Retrospective Studies , Twins
14.
J Pediatr Endocrinol Metab ; 10(3): 291-4, 1997.
Article in English | MEDLINE | ID: mdl-9388821

ABSTRACT

Recombinant human growth hormone (rhGH) may reduce the catabolic side effects of steroid therapies on children and adults, but this has never been studied in preterm infants. We performed a pilot study on 5 extremely low birth weight preterm infants (gestational age 27 +/- 3 wks, birth weight 824 +/- 160 g) still on mechanical ventilation for bronchopulmonary dysplasia at the postnatal age of 35 +/- 9 days. All were treated for 7 days with dexamethasone (0.5 mg/kg/d i.v.) and subcutaneous rhGH at different doses: 0.1 (n = 1), 0.2 (n = 2) or 0.3 (n = 2) IU/kg/day. Nutrition was kept stable. After 7 days all subjects improved their respiratory condition but body weight remained the same and urinary urea nitrogen and C-peptide were significantly higher (p < 0.001). rhGH intake strongly related to urinary excretion of urea nitrogen (r = 0.78) and C-peptide (r = 0.88). Dexamethasone improves the pulmonary function of very preterm infants with bronchopulmonary dysplasia but induces growth arrest and catabolism which are not prevented, and may be worsened, by rhGH.


Subject(s)
Bronchopulmonary Dysplasia/drug therapy , Dexamethasone/adverse effects , Human Growth Hormone/therapeutic use , Infant, Premature , Infant, Very Low Birth Weight , Alanine Transaminase/blood , Bilirubin/blood , Birth Weight , Blood Urea Nitrogen , C-Peptide/urine , Cholesterol/blood , Dexamethasone/therapeutic use , Gestational Age , Growth Disorders/chemically induced , Human Growth Hormone/administration & dosage , Humans , Infant , Infant, Newborn , Nitrogen/urine , Pilot Projects , Respiration, Artificial , Urea/urine
15.
Pediatr Cardiol ; 18(1): 67-71, 1997.
Article in English | MEDLINE | ID: mdl-8960499

ABSTRACT

A premature baby had severe hypertension associated with idiopathic arterial calcification of infancy. Despite the fact that there was laboratory evidence of renin-mediated hypertension, the disease was refractory to specific renin antagonist and failed to respond to conventional medical treatment. Prostaglandin E1 (PGE1) infusion (dosage range 0.017-0.068 microgram/kg/min) promptly controlled hypertension on two occasions. The drug was given for a total of 65 days and then stopped after the appearance of severe thrombocytopenia; other side effects included sporadic hyperthermia and irritability. Blood pressure was then stabilized satisfactory by a multiple-antihypertensive regimen. In the light of these findings, we believe that PGE1 infusion is a possible therapeutic alternative for babies with idiopathic arterial calcification complicated by severe hypertension refractory to conventional treatment.


Subject(s)
Calcinosis/complications , Hypertension/drug therapy , Prostaglandins E/therapeutic use , Echocardiography , Female , Humans , Hypertension/etiology , Infant, Newborn , Infant, Premature , Prostaglandins E/adverse effects
16.
Br J Cancer ; 76(12): 1617-22, 1997.
Article in English | MEDLINE | ID: mdl-9413951

ABSTRACT

Electrochemotherapy combines bleomycin and local electric pulses that allow cell permeabilization and free access of bleomycin to its intracellular target. We report the first veterinarian clinical trial of electrochemotherapy in 12 cats with spontaneous large soft-tissue sarcomas that suffered relapse after treatment with conventional therapies. Permeabilizing electric pulses were delivered using external surface electrodes, as well as new needle-shaped electrodes that were designed to be inserted in tumours for more effective treatment of several-centimetre-thick tumour nodules. The electric pulses were applied to the tumours several times from 4 to 15-30 min after a bolus intravenous injection of 0.5 mg kg(-1) bleomycin. Tolerance to treatment was excellent without general side-effects. The cats showed local inflammatory reactions for a few days and disease stabilization lasted from 2 weeks to 7 months. One partial regression was observed, and the general absence of nodule volume decrease can be explained by local fibrotic reactions. Histological analysis of biopsies also revealed massive tumour cell death. The cats' lifespan increased (P<<0.001), with a mean survival time of 6.1 months (maximum 18 months) compared with 0.8 months (maximum 1.5 months) for a group of 11 untreated control cats displaying similar carcinological features. Electrochemotherapy is clearly effective as a salvage treatment for large spontaneous solid tumours in adverse clinical situations and this is promising for future applications.


Subject(s)
Antibiotics, Antineoplastic/therapeutic use , Bleomycin/therapeutic use , Cat Diseases/therapy , Electric Stimulation Therapy , Sarcoma/veterinary , Animals , Cat Diseases/pathology , Cats , Sarcoma/pathology , Sarcoma/therapy
17.
Ital J Gastroenterol Hepatol ; 29(5): 420-6, 1997 Oct.
Article in English | MEDLINE | ID: mdl-9494851

ABSTRACT

BACKGROUND: Ribavirin increases the efficacy of alpha-interferon in chronic hepatitis C, but accumulates in erythrocytes causing haemolysis. AIMS: To reduce this side effect we conjugated ribavirin with lactosaminated poly-L-lysine. METHODS: In mice administered with the same dose of free or conjugated [3H]ribavirin we determined the levels of radioactivity in liver and erythrocytes and measured the hepatic concentrations of ribavirin triphosphate. Moreover, we determined the doses of free and conjugated ribavirin producing a 50% reduction in the virus titre (ED50) in liver of mice infected with murine hepatitis virus. RESULTS: In mice treated with the conjugate, the ratio dpm in liver/dpm in erythrocytes was 2.2- or 4.7-fold higher than in animals administered with the free drug given intramuscularly or orally, respectively. The concentration of [3H]ribavirin triphosphate was found to be 2-fold higher in mice injected with the conjugated drug than in animals orally treated with free ribavirin. In murine hepatitis virus infected mice, the ED50 was 27.4 micrograms/g for conjugated ribavirin and 47.2 micrograms/g for the free drug. CONCLUSIONS: These results support the possibility that conjugated ribavirin may produce the same pharmacological activity in liver as the free drug but with a reduced haemolysis.


Subject(s)
Antiviral Agents/pharmacokinetics , Erythrocytes/metabolism , Liver/metabolism , Ribavirin/pharmacokinetics , Amino Sugars , Animals , Antiviral Agents/administration & dosage , Liver/virology , Mice , Mice, Inbred BALB C , Mice, Inbred Strains , Murine hepatitis virus/drug effects , Polylysine , Ribavirin/administration & dosage , Tritium
18.
Gene Ther ; 3(12): 1104-12, 1996 Dec.
Article in English | MEDLINE | ID: mdl-8986437

ABSTRACT

The production of human interleukin-2 (hIL-2) local to the tumor site by engineered histoincompatible cells has been shown in various murine models to promote a strong immune response leading to tumor growth inhibition or rejection. To assess whether this strategy would be similarly applicable for treatment of primary neoplastic cells, two naturally occurring tumors were used as preclinical models; the highly metastatic melanoma of the dog and the low metastatic fibrosarcoma of the cat. We demonstrate that both cats and dogs when treated by tumor surgery, radiotherapy and repeated local injections of xenogeneic Vero cells secreting high levels of hIL-2 relapse less frequently and survive longer than control animals treated by surgery and radiotherapy alone. Local secretion of hIL-2 by the xenogeneic cells is shown to be necessary for the induction of an optimal antitumor effect. Moreover, the safety of the procedure was demonstrated in both animal models and through extensive toxicological analysis performed in rats. These results confirm for the first time to our knowledge the safety and therapeutic potential of a gene transfer strategy in animals with spontaneous metastatic and nonmetastatic tumors.


Subject(s)
Cat Diseases/therapy , Dog Diseases/therapy , Fibrosarcoma/genetics , Genetic Therapy , Histocompatibility , Interleukin-2/genetics , Melanoma/veterinary , Vero Cells/transplantation , Animals , Cat Diseases/radiotherapy , Cat Diseases/surgery , Cats , Cell Survival , Chlorocebus aethiops , Combined Modality Therapy , Dog Diseases/radiotherapy , Dog Diseases/surgery , Dogs , Female , Fibrosarcoma/radiotherapy , Fibrosarcoma/secondary , Fibrosarcoma/surgery , Fibrosarcoma/therapy , Gene Transfer Techniques , Genetic Therapy/adverse effects , Genetic Vectors , Humans , Interleukin-2/administration & dosage , Male , Melanoma/radiotherapy , Melanoma/secondary , Melanoma/surgery , Melanoma/therapy , Rats , Rats, Sprague-Dawley , Recurrence , Vero Cells/immunology
19.
Antimicrob Agents Chemother ; 40(9): 2034-8, 1996 Sep.
Article in English | MEDLINE | ID: mdl-8878576

ABSTRACT

Among a series of unmodified phosphodiester (PO)-oligodeoxynucleotides (PO-ODNs) complementary to some of the human immunodeficiency virus type 1 (HIV-1) regulatory genes, several PO-ODN sequences complementary to the vpr gene (PO-ODNs-a-vpr, where a-vpr is the antisense vpr sequence) emerged as potent inhibitors (at concentrations of 0.8 to 3.3 microM) of HIV-1 multiplication in de novo infected MT-4 cells, while they showed no cytotoxicity for uninfected cells at concentrations up to 100 microM. Unlike phosphorothioate counterparts, PO-ODN-a-vpr sequences were not inhibitory to HIV-2 multiplication in de novo infected C8166 cells and neither prevented the fusion between chronically infected and bystander CD4+ cells nor inhibited the activity of the HIV-1 reverse transcriptase in enzyme assays. Moreover, they were not inhibitory to HIV-1 multiplication in chronically infected cells. Delayed addition experiments showed that PO-ODNs-a-vpr inhibit an event in the HIV-1 replication cycle following adsorption to the host cell, but preceding reverse transcription. Structure-activity relationship studies indicated that the antiviral activity of the test PO-ODN-a-vpr sequences is not related to an antisense mechanism but to the presence, within the active sequences, of contiguous guanine residues. Physical characterization of the test PO-ODNs suggested that the active structure is a tetramer stabilized by G quartets (i.e., four G residues connected by eight hydrogen bonds).


Subject(s)
Anti-HIV Agents/pharmacology , HIV-1/drug effects , Oligonucleotides/pharmacology , Anti-HIV Agents/analysis , Cell Fusion , Cells, Cultured , Circular Dichroism , Genes, Viral , HIV Infections/virology , HIV Reverse Transcriptase/antagonists & inhibitors , HIV-2/drug effects , Humans , Oligonucleotides/analysis , Structure-Activity Relationship , Virus Replication/drug effects
20.
Minerva Pediatr ; 48(9): 383-5, 1996 Sep.
Article in English | MEDLINE | ID: mdl-8968151

ABSTRACT

A case of severe, acute accidental theophylline intoxication in a 6-week old preterm infant treated with peritoneal dialysis is reported. Theophylline concentrations in plasma, urine and in the peritoneal lavage fluid were measured during all the procedure. With dialysis theophylline half-life was reduced to 14.8 hours, despite a plasmatic peak level of 133 micrograms/ml, and a significative amount of the drug was removed from the body, leading to a rapid and complete recovery of the child. In our experience peritoneal dialysis can be regarded as a first line emergency procedure in very sick infants with severe theophylline intoxication when more sophisticated methods are not available.


Subject(s)
Ascitic Fluid/chemistry , Peritoneal Dialysis , Theophylline/adverse effects , Theophylline/analysis , Humans , Infant , Infant, Newborn , Infant, Premature , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...